title: [Diffuse large B-cell lymphoma of testis: a clinicopathologic and immunophenotypic study of 58 cases].
abstract: OBJECTIVE
  To investigate the clinicopathologic features, immunophenotype, diagnosis and differential diagnosis, and prognostic factors of testicular diffuse large B-cell lymphoma (DLBCL).
  
  
  METHODS
  The clinical and pathologic profiles of 58 cases of testicular DLBCL were investigated.Immunohistochemical stainings and EBER1/2 in situ hybridization were performed on formalin fixed tissues.
  
  
  RESULTS
  The average age of the patients was 62.1 years, and the median age was 65 years. The course of disease was short in most of the cases. Clinical stages at diagnosis were mainly stage I or II (87.9%, 51/58). Forty eight patients (82.8%) had unilateral testis involvement. Inguinal lymphadenopathy was observed in 12 (20.7%) patients and the other organs were seldom involved. Morphologically, centroblast-like neoplastic cells infiltrated interstitial tissue of testis diffusely and invaded into seminiferous tubules. Tunica albuginea and vessels were involved in 14 (24.1%) and 10 (17.2%) patients, respectively. Immunophenotype analysis showed predominant non-GCB type of DLBCL (48/58, 82.8%) by Hans classification. No EBV infection was detected. Follow-up data were available in 48 (82.8%) patients. Twenty eight patients (58.3%) died of the disease. One-year, 3-year, and 5-year overall survivals were 55.7%, 31.6% and 27.6%, respectively. Age (older than 60 years), B-symptoms, high serum level of LDH, advanced Ann Arbor stage as well as lack of combination of therapy were associated with a poor prognosis.
  
  
  CONCLUSIONS
  This large series of testicular DLBCL mainly present with local disease at diagnosis. Most cases show non-GCB immunophenotype. Despite early clinical stage at presentation, the prognosis is poor. Combined chemotherapy postoperation may prolong survival of the patients.
authors: Department of Pathology, West China Hospital, Sichuan University, Chengdu 610041, China.
authors: Zhi-rong
authors: ZR
authors: Yang
authors: Cheng-feng
authors: CF
authors: Bi
authors: Wen-yan
authors: WY
authors: Zhang
authors: Qun-pei
authors: QP
authors: Yang
authors: Wei-ping
authors: WP
authors: Liu
mesh_terms: D000293:Adolescent; D000328:Adult; D000368:Aged; D000369:Aged, 80 and over; D000971:Antineoplastic Combined Chemotherapy Protocols / Q000627:therapeutic use; D002648:Child; D003520:Cyclophosphamide / Q000627:therapeutic use; D004317:Doxorubicin / Q000627:therapeutic use; D005500:Follow-Up Studies; D006801:Humans; D016130:Immunophenotyping; D050835:Interferon Regulatory Factors / Q000378:metabolism; D045022:Lactate Dehydrogenases / Q000378:metabolism; D008207:Lymphatic Metastasis; D016403:Lymphoma, Large B-Cell, Diffuse / Q000188:drug therapy / Q000276:immunology* / Q000473:pathology* / Q000601:surgery; D008297:Male; D008875:Middle Aged; D009367:Neoplasm Staging; D015260:Neprilysin / Q000378:metabolism; D009919:Orchiectomy; D011241:Prednisone / Q000627:therapeutic use; D051560:Proto-Oncogene Proteins c-bcl-6 / Q000378:metabolism; D015996:Survival Rate; D013736:Testicular Neoplasms / Q000188:drug therapy / Q000276:immunology* / Q000473:pathology* / Q000601:surgery; D014750:Vincristine / Q000627:therapeutic use; D055815:Young Adult; D000099218:Interferon Regulatory Factor-4
chemical_list: D003520:Cyclophosphamide; D004317:Doxorubicin; D050835:Interferon Regulatory Factors; D045022:Lactate Dehydrogenases; D015260:Neprilysin; D011241:Prednisone; D051560:Proto-Oncogene Proteins c-bcl-6; D014750:Vincristine; D000099218:Interferon Regulatory Factor-4